TP53 Mutation Detection Kit with Next Generation Sequence Analysis
Li-Fraumeni syndrome (LFS) is a cancer susceptibility syndrome associated with an increased risk of developing soft tissue sarcoma, osteosarcoma, premenopausal breast cancer, brain tumours, adrenocortical carcinoma and leukemia. LFS related cancers often occur in childhood or young adulthood. Survivors of these cancers are at risk of contracting other cancers with advancing age.
Mutations in the TP53 gene can be identified in more than 70% of cases diagnosed with the clinical LFS according to clinical criteria and any history of cancer in the family. To date, no other gene has been identified that causes this syndrome. More than 95% of the responsible variants in this gene can be detected by sequence analysis of the coding regions of the TP53 gene.